1,1-Dimethoxy-2-propanamine - CAS 57390-38-2
Catalog: |
BB055853 |
Product Name: |
1,1-Dimethoxy-2-propanamine |
CAS: |
57390-38-2 |
Synonyms: |
(2,2-Dimethoxy-1-methylethyl)amine; 2-Aminopropanal Dimethyl Acetal; 2-Aminopropionaldehyde Dimethyl Acetal |
IUPAC Name: | 1,1-dimethoxypropan-2-amine |
Description: | 1,1-Dimethoxy-2-propanamine, can be used for the synthesis of N-protected α-amino aldehydes occur as C-terminal units of peptide aldehydes with enzyme inhibitor activity, such as Leupeptin. They can also be used for the preparation of amino sugars, and unusual amino acids. |
Molecular Weight: | 119.16 |
Molecular Formula: | C5H13NO2 |
Canonical SMILES: | CC(C(OC)OC)N |
InChI: | InChI=1S/C5H13NO2/c1-4(6)5(7-2)8-3/h4-5H,6H2,1-3H3 |
InChI Key: | GZOKAVHTSXSLNB-UHFFFAOYSA-N |
References: | Bringmann, G., et al. J. Synthesis, 608 (1989). |
GHS Hazard Statement: | H226 (100%): Flammable liquid and vapor [Warning Flammable liquids] |
Precautionary Statement: | P210, P233, P240, P241, P242, P243, P260, P264, P280, P301+P330+P331, P302+P361+P354, P303+P361+P353, P304+P340, P305+P354+P338, P316, P321, P363, P370+P378, P403+P235, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
US-2022041606-A1 | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 | 20200728 |
JP-2021183586-A | Heterocyclic compound | 20200522 |
WO-2021234450-A1 | 1-((1h-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2h-imidazol-2-one derivatives and related compounds as gpr139 antagonists for the treatment of e.g. depression | 20200522 |
WO-2021122978-A1 | Non aqueous crosslinkable composition | 20191219 |
WO-2021027304-A1 | Analgesic compound, preparation method therefor, and pharmaceutical use thereof | 20190814 |
CN-112789276-A | Analgesic compounds, their preparation and their pharmaceutical use | 20190814 |
US-2020109148-A1 | Cardiac sarcomere inhibitors | 20180831 |
CA-3110237-A1 | Cardiac sarcomere inhibitors | 20180831 |
BR-112021003496-A2 | compound, pharmaceutical composition, and, methods for treating heart disease, for treating a disease or condition associated with hypertrophic cardiomyopathy, or condition that is associated with secondary thickening of the left ventricular wall, or condition that is associated with the small cavity of the left ventricle and cavity obliteration, hyperdynamic contraction of the left ventricle, myocardial ischemia or cardiac fibrosis, or a condition selected from muscular dystrophies and glycogen storage diseases to inhibit cardiac sarcomere | 20180831 |
KR-20210068422-A | cardiac eradication inhibitors | 20180831 |
Complexity: | 54.4 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 119.094628657 |
Formal Charge: | 0 |
Heavy Atom Count: | 8 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 119.094628657 |
Rotatable Bond Count: | 3 |
Topological Polar Surface Area: | 44.5Ų |
Undefined Atom Stereocenter Count: | 1 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | -0.4 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
-
[112157-39-8]
N2-[(Phenylmethoxy)carbonyl]-L-lysine tert-Butyl Ester
-
[1365727-07-6]
6-Methyldi(ondansetron-3-de(1,2-dimethyl-1H-imidazole))
-
(3R,4R)-tert-Butyl 3-((6,7-Dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidine-1-carboxylate
-
(2R,5S,10aS,10bS)-10b-Hydroxy-5-isopropyl-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazine-2-carboxylic Acid
-
[31431-28-4]
(4-Amino-3-nitrophenyl)(4-methylphenyl)-methanone
-
(I2,3S)-23-Des(methoxyimino)-23-[(methylsulfanyl)methoxy]moxidectin O-TBS
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS